Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#2 Fake World Assets Fake World Assets +18.28%
#3 Status Status +17.90%
#4 GoPlus Security GoPlus Security +11.51%
#5 Ontology Gas Ontology Gas +10.01%
#6 Bedrock Bedrock +7.70%
#7 DMT-NAT DMT-NAT +7.61%
#8 Cap Cap +6.73%
#9 Provenance Blockchain Provenance Blockchain +6.73%
#10 Janction Janction +5.45%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
설정
언어
한국어
통화
USD
테마
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
주식 순위 #33997
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
주가
$0.1502
마지막 동기화: 2024-11-04
시가총액
$6.43M
변동 (1일)
-5.45%
변동 (1년)
0.00%
국가
US
거래 Renalytix Plc (RNLX)

카테고리

Healthcare
Renalytix Plc (RNLX)의 발행 주식 수
September 2024 기준 발행 주식 수: 52.85M
Renalytix Plc의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 52.85M입니다. June 2023 말 기준 회사는 41.11M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Renalytix Plc (RNLX)의 발행 주식 수 기록 (2018 ~ 2026)
매년 말 기준 발행 주식 수
연도 발행 주식 수 변화
2026 (TTM) 52.85M -2.29%
2024 54.09M 31.59%
2023 41.11M 20.93%
2022 33.99M -4.07%
2021 35.43M 22.38%
2020 28.95M 36.05%
2019 21.28M 1.82%
2018 20.90M 0.00%
유사 기업 또는 경쟁사의 발행 주식 수
회사 발행 주식 수 차이 국가
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
 453.00M 757.16%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
 104.48M 97.70%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
 205.38M 288.62%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
 179.92M 240.44%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
 - -
US